Literature DB >> 15324808

Identification and analysis of the core biosynthetic machinery of tubulysin, a potent cytotoxin with potential anticancer activity.

Axel Sandmann1, Florenz Sasse, Rolf Müller.   

Abstract

Myxobacteria are well known for their biosynthetic potential, especially for the production of cytotoxic compounds with potential anticancer activities. The tubulysins are currently in preclinical development. They are produced in very low quantities, and genetic manipulation of producing strains has never been accomplished. We report the development of a mariner-based transposon mutagenesis system for Angiococcus disciformis An d48. Extracts from a library of 1200 mutants were analyzed for the presence of tubulysin by a microscopic cell nucleus fragmentation bioassay. The transposition sites of four tubulysin-negative mutants were identified by vector recovery, which led to the identification and the sequencing of the corresponding core biosynthetic gene locus. Sequence analysis of more than 80,000 bp reveals an unusual multimodular hybrid polyketide synthase/peptide synthetase assembly line with a variety of unprecedented features.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15324808     DOI: 10.1016/j.chembiol.2004.05.014

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  16 in total

1.  Insights into an unusual nonribosomal peptide synthetase biosynthesis: identification and characterization of the GE81112 biosynthetic gene cluster.

Authors:  Tina M Binz; Sonia I Maffioli; Margherita Sosio; Stefano Donadio; Rolf Müller
Journal:  J Biol Chem       Date:  2010-08-14       Impact factor: 5.157

2.  The unique DKxanthene secondary metabolite family from the myxobacterium Myxococcus xanthus is required for developmental sporulation.

Authors:  Peter Meiser; Helge B Bode; Rolf Müller
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-05       Impact factor: 11.205

3.  Chemotherapeutic evaluation of a synthetic tubulysin analogue-dendrimer conjugate in c26 tumor bearing mice.

Authors:  William C Floyd; Gopal K Datta; Shinichi Imamura; Heidi M Kieler-Ferguson; Katherine Jerger; Andrew W Patterson; Megan E Fox; Francis C Szoka; Jean M J Fréchet; Jonathan A Ellman
Journal:  ChemMedChem       Date:  2011-01-03       Impact factor: 3.466

Review 4.  Analysis of myxobacterial secondary metabolism goes molecular.

Authors:  Helge B Bode; Rolf Müller
Journal:  J Ind Microbiol Biotechnol       Date:  2006-02-21       Impact factor: 3.346

Review 5.  The Uncommon Enzymology of Cis-Acyltransferase Assembly Lines.

Authors:  Adrian T Keatinge-Clay
Journal:  Chem Rev       Date:  2017-04-10       Impact factor: 60.622

6.  Structural and Functional Trends in Dehydrating Bimodules from trans-Acyltransferase Polyketide Synthases.

Authors:  Drew T Wagner; Jia Zeng; Constance B Bailey; Darren C Gay; Fang Yuan; Hannah R Manion; Adrian T Keatinge-Clay
Journal:  Structure       Date:  2017-06-15       Impact factor: 5.006

7.  Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product.

Authors:  Gurmeet Kaur; Melinda Hollingshead; Susan Holbeck; Vesna Schauer-Vukasinović; Richard F Camalier; Alexander Dömling; Seema Agarwal
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

Review 8.  Transposition of fly mariner elements into bacteria as a genetic tool for mutagenesis.

Authors:  Mathieu Picardeau
Journal:  Genetica       Date:  2009-09-13       Impact factor: 1.082

9.  Total synthesis and biological evaluation of tubulysin U, tubulysin V, and their analogues.

Authors:  Ranganathan Balasubramanian; Bhooma Raghavan; Adrian Begaye; Dan L Sackett; Robert A Fecik
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

10.  Pretubulysin: from hypothetical biosynthetic intermediate to potential lead in tumor therapy.

Authors:  Jennifer Herrmann; Yasser A Elnakady; Romina M Wiedmann; Angelika Ullrich; Manfred Rohde; Uli Kazmaier; Angelika M Vollmar; Rolf Müller
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.